ROTE WILLIAM E.
Known title: Senior Vice President, R&DCIK: 0001698262
Associated companies
Transaction History
| TVTX | ▲ Buy | Option Exercise | 350 | $6K | 9/16/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 55,000 | $850K | 9/16/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 57,500 | $1.5M | 9/16/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 65,104 | $4.1M | 9/16/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 47,746 | $3.0M | 9/16/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 39,000 | $985K | 9/15/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 39,650 | $712K | 9/15/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 63,907 | $4.0M | 9/15/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 29,021 | $1.8M | 9/15/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 3,000 | $191K | 9/15/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 270 | $18K | 9/15/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,763 | $121K | 5/6/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 4,250 | $0 | 5/4/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 9,100 | $356K | 4/22/2026 | View on chart |
| TVTX | ▲ Buy | Grant | 14,000 | $0 | 4/13/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 12,446 | $409K | 2/3/2026 | View on chart |
| TVTX | ▲ Buy | Grant | 20,090 | $0 | 1/31/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 60,000 | $1.2M | 12/24/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 60,000 | $2.4M | 12/24/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 3,198 | $67K | 5/5/2025 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 4,920 | — | 5/2/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 5,200 | $122K | 2/12/2025 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 8,000 | — | 2/10/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 8,951 | $177K | 2/3/2025 | View on chart |
| TVTX | ▲ Buy | Grant | 21,500 | $0 | 1/31/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,437 | $47K | 1/22/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 4,387 | $51K | 9/9/2024 | View on chart |
| TVTX | ▲ Buy | Grant | 6,750 | $0 | 9/5/2024 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,174 | $19K | 2/1/2024 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,590 | $23K | 2/1/2024 | View on chart |
| TVTX | ▲ Buy | Grant | 25,000 | $0 | 1/31/2024 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,062 | $18K | 1/23/2024 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,815 | $27K | 9/5/2023 | View on chart |
| TVTX | ▲ Buy | Grant | 3,300 | $0 | 8/31/2023 | View on chart |
| TVTX | ▼ Sell | Open Market | 825 | $14K | 5/10/2023 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,590 | $58K | 2/1/2023 | View on chart |
| TVTX | ▲ Buy | Grant | 20,250 | $0 | 1/31/2023 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,062 | $44K | 1/24/2023 | View on chart |
| TVTX | ▼ Sell | Open Market | 750 | $16K | 5/11/2022 | View on chart |
| TVTX | ▼ Sell | Open Market | 813 | $17K | 5/11/2022 | View on chart |
| TVTX | ▲ Buy | Grant | 9,840 | $0 | 1/31/2022 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,125 | $31K | 1/31/2022 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,875 | $47K | 1/24/2022 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,500 | $69K | 1/11/2022 | View on chart |
| TVTX | ▲ Buy | Grant | 5,000 | $0 | 1/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Travere Shares Drop 6.7% Ahead of New FILSPARI Data
Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.
Travere Shares Drop 6.7% Ahead of New FILSPARI Data. Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.